AuthorisedHuman Pharmacology (Phase I)- First administration to humansInterventional

A study to test single and multiple doses of MER511 given to adults with Graves’ disease

This study is exploring a new medication called MER511 for adults who have Graves' disease, a condition where the immune system attacks the thyroid gland, making it overactive. This is a very early-stage study, meaning it's the first time MER511 will be given to people. The main goals are to understand if MER511 is safe, what side effects it might cause, and how the body handles it. Researchers will test different amounts of MER511 to see how it works and how long it stays in the body. This is an important step in developing new treatments for Graves' disease to potentially improve how people manage their condition in the future.

At a glance

Status

Authorised

Phase

Human Pharmacology (Phase I)- First administration to humans

Sponsor

Merida Biosciences Inc.

Enrolment target

Start

22 May 2026

Graves’ disease

What is this study about?

Imagine your body's thermostat, the thyroid gland, working too hard. That's what happens in Graves' disease, causing symptoms like a fast heartbeat, weight loss, and feeling anxious. Scientists are always looking for new ways to help people with this condition. This particular study is about a new medicine called MER511.

This is a 'first-in-human' study, which is a very early step in testing a new medicine. It means that MER511 hasn't been given to people before. The main aim is to make sure it's safe to use and to understand how your body reacts to it. Researchers will be giving different small amounts of MER511 to volunteers to see what happens.

By taking part, you'd be helping scientists learn crucial information about MER511. This could, in time, lead to a new treatment option for Graves' disease, potentially offering a different way to manage symptoms and improve quality of life for many people in the future.

Key takeaways

This is an early study of a new medicine (MER511) for Graves' disease.
It's the first time MER511 has been given to people.
The main aim is to check if the medicine is safe and how your body handles it.
Adults with Graves' disease are being invited to take part.
Participation involves taking MER511 and having regular health checks.
It could help find new treatments for Graves' disease in the future.

Who may be eligible?

This study is looking for adults aged 18 and over who have Graves' disease. They are inviting both men and women to take part.

To join, you would need to meet certain health requirements. These are carefully checked by the study doctors to make sure it's safe for you to participate and that the results of the study are clear. You will have a thorough health check to determine if this study is right for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a diagnosis of Graves' disease?
Are you able to attend appointments at the study clinic?
Are you willing to potentially receive a new, untested medicine?

Answer every question to see your result.

What does participation involve?

If you decide to take part, you would receive the new medicine, MER511. This would involve a series of visits to the study clinic over a period of time. During these visits, the study team would carefully monitor your health, likely taking blood samples, checking your vital signs (like blood pressure and heart rate), and asking about any side effects you might experience. You would receive either a single dose or several doses of MER511.

The total amount of time you would be involved in the study, including all visits and follow-up checks after you've stopped taking the medicine, would be fully explained to you before you agree to participate. You would know the full schedule upfront.

Potential risks and benefits

Potential benefits of taking part could include gaining access to a new experimental medicine for Graves' disease before it's widely available, and closely monitored medical care during the study. You would also contribute valuable information that could help others with Graves' disease in the future. However, there are potential risks, as MER511 is a new medicine and its side effects are not yet fully known. You might experience unexpected reactions, and the medicine might not help your condition. It is very important to remember that you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Spain

Common questions

What is Graves' disease?

Graves' disease is a condition where your immune system mistakenly attacks your thyroid gland, making it produce too many thyroid hormones. This causes an overactive thyroid.

What is MER511?

MER511 is a new medicine being tested for the first time in people, to see if it can help those with Graves' disease.

What does 'first-in-human' mean?

It means this is the very first time this new medicine is being given to people to test its safety and how it works in the human body.

Will this medicine cure my Graves' disease?

It's too early to say if MER511 will cure Graves' disease. Early studies like this focus on safety and understanding how the medicine works, not its long-term effects or cure potential.

Do I have to stop my current Graves' disease medication to join?

The study doctors will discuss all your current medications with you and explain if any changes would be needed for you to take part. This will be an important part of checking if you are suitable for the study.